糖尿病患者血脂异常管理新动向被引量：3

导出

摘要近日,美国糖尿病学会（ADA）颁布了2015年ADA糖尿病医学诊疗标准（以下简称ADA指南）[1],美国内分泌医师协会（AACE）和美国内分泌学会（ACE）也联合颁布了2015年AACE/ACE糖尿病综合治疗方案临床实践指南（以下简称AACE/ACE指南）[2].学习这两个指南中血脂异常管理的重要内容,可了解目前糖尿病患者血脂异常管理的新动向.

作者赵旺赵水平

机构地区中南大学湘雅二医院心血管内科

出处《中华内科杂志》 CAS CSCD 北大核心 2016年第3期177-180,共4页 Chinese Journal of Internal Medicine

关键词美国糖尿病学会血脂异常管理患者临床实践指南美国内分泌学会综合治疗方案诊疗标准

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献13

1Introduction[J]. Diabetes Care, 2015,38 Suppl:S1-S2.
2Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American association of clinical endocrinologists and american college of endocrinology-clinical practice guidelines for developing a diabetes mellitus comprehensive care plan-2015[J]. Endocr Pract,2015,21 Suppl 1:1-87.
3Stone NJ, Robinson JG, Lichtenstein AH, et al.2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol,2014,63(25 Pt B):2889-2934.
4孙艺红.餐后糖代谢异常与心血管疾病的进展[J].中华内科杂志,2013,52(9):789-790. 被引量：8
5Meek C, Wierzbicki AS,Jewkes C,et al. Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients : an observational study[J]. Curr Med Res Opin, 2012,28(3):371-378.
6ACCORD Study Group,Ginsberg HN,Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus[J]. N Engl J Med,2010,362(17);1563-1574.
7Ziaeian B, Dinkier J, Watson K. Implementation of the 2013 American College of Cardiology/American Heart Association Blood Cholesterol Guideline Including Data From the Improved Reduction of Outcomes : Vytorin Efficacy International Trial[J]. Rev Cardiovasc Med, 2015 , 16(2):125-130.
8Jones PH,Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin[J]. Am J Cardiol,2005,95(1):120-122.
9AIM-HIGH Investigators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy[J]. N Engl J Med,2011,365(24):2255-2267.
10赵水平,陈雅琴.非他汀类调脂药物应用地位评价[J].中华内科杂志,2015,54(4):284-287. 被引量：2

二级参考文献35

1Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med,2010 ,362 :1090-1101.
2Tushuizen ME, Diamant M, Heine RJ. Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes. Postgrad Med J, 2005,81:1-6.
3Teno S, Uto Y, Nagashima H, et al. Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetes. Diabetes Care ,2000 ,23 :1401-1406.
4Uetani E, Tabara Y, Igase M,et al. Postprandial hypertension, an overlooked risk marker for arteriosclerosis. Atherosclerosis, 2012, 224:500-505.
5Chapman M J, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J,2011,32 : 1345-1361.
6Teno S, Uto Y, Nagashima H, et al. Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetes. Diabetes Care ,2000,23 : 1401-1406.
7Delorme S, Chiasson JL. Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus. Curr Opin Phannacol,2005,5 : 184- 189.
8DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality:comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med, 2001 , 161:397405.
9Nakagami T; DECODA Stndy Group. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia,2004,47:385-394.
10Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance:the STOP-NIDDM trial. JAMA, 2003, 90:486-494.